GSK adds former Merck CFO to board

pharmafile | March 7, 2011 | Appointment | Sales and Marketing GSK, GlaxoSmithKline, Judy Lewent, Stacey Cartwright, appointment, sales and marketing 

GlaxoSmithKline has appointed Judy Lewent to its board as a non-executive director.

She has previously served as an executive VP and chief financial officer at Merck & Co, and currently serves on the boards of Dell, Thermo Fisher Scientific and Motorola Solutions.

GSK has also appointed Stacey Cartwright to its board as a non-executive director and both she and Judy will join the firm’s audit and risk committee.

Advertisement

Stacey current serves as chief financial officer at Burberry Group, where she also holds responsibility for IT, legal and intellectual property, and runs planning and pricing for the business.

Commenting on the appointments, GSK chairman Sir Christopher Gent said: “I am delighted to welcome Judy and Stacey to the Board of GSK. Their experience of global business and finance, and their respective knowledge of the pharmaceutical industry and consumer brands, will bring a fresh, external perspective to the board.”

Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Multiple myeloma treatment approved in Japan

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …

David Wheadon appointed to board of directors at Seaport Therapeutics

This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

The Gateway to Local Adoption Series

Latest content